Preclinical safety and efficacy of andexanet alfa in animal models
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13768
Abstract: Essentials There is currently no approved reversal agent for factor Xa (FXa) inhibitors Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors Andexanet reduced blood loss and anticoagulation markers in rivaroxabanâanticoagulated… read more here.
Keywords: alfa animal; efficacy andexanet; safety efficacy; preclinical safety ... See more keywords